Navigation Links
AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies
Date:4/20/2009

-- Key Data are New Releases for the Company Building on Milestones with Recent FDA Meetings and Technology Discoveries --

DENVER, April 20 /PRNewswire-FirstCall/ -- DXL625 monoclonal antibodies appear to be superior to commercial-stage antibodies in their ability to attach and deplete NHL in late stage pre-clinical studies, according to research conducted at InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology. The potency was achieved with comparable safety even at levels one hundred times that required for therapeutic efficacy, according to several studies presented at the American Association of Cancer Research (AACR) 100th Annual Meeting this past weekend. DXL625 is designed to bind CD20, a protein receptor expressed on normal B cells and over-expressed on cancerous B cells.

InNexus has previously announced that the United States Food and Drug Administration had completed its comprehensive review of the development plans for DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL). InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing plans. The FDA noted at the time that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus.

"The studies are an important validation of our core drug discovery platform and confirm our ability to significantly advance the state of the art in developing potentially superior biologics for major medical and commercial opportunities," said Jeff Morhet, Chairman and CEO at InNexus.

InNexus and institutional researchers authored two studies presented during the AACR meeting. These included:

-- One study, to determine whether the superior activity of the modified anti-CD20 human-mouse chimeric antibody exposed unexpected adverse activity that may not have been seen with the less cytotoxic unmodified antibody. The study determined that the increased target activity and cytotoxicity of DXL-modified anti-CD20 does not affect safety even at doses 100 times that normally required for efficacy.

"We have confirmed that the dose of maximally effective DXL-peptide conjugated anti-CD20 DXL625 retains the impressive safety historically seen with therapeutic anti-CD20 antibodies," Dr. Thomas Kindt, Chief Scientific Officer of InNexus.

-- The second study defined the ability to "program" self-binding properties into antibodies. These "self-binding" interactions were seen to effectively increase the binding strength between the antibody and the target antigen, as determined repeatedly by measurable kinetic changes.

InNexus' AACR presentations are titled, "A Novel High Avidity Anti-CD20 With Markedly Increased Cytotoxicity Shows No Systemic Toxicity In The Cynomolgus Monkey At A Dose 100-Fold Above The Anticipated Therapeutic Dose", (AACR# 1231) and "Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic Binding Kinetics", (AACR# 1230). Posters and company representatives will also be available within the AACR Antibody and Antibody Targets Session from 1:00-5:00 PM on April 19th in Hall B-F, Poster Section 12. The posters will also be available via the InNexus website beginning April 19th.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fralex reaches 100th patient milestone in fibromyalgia study
2. WolfPAC(sm) Integrated Risk Management Announces 100th Sale
3. eRT Completes Milestone 100th Thorough QT Study
4. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
5. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
6. Sinovac Announces Postponement of Annual General Meeting
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
11. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... 10, 2016  The Maryland House of Delegates and ... that University of Maryland School of Medicine Dean ... of Maryland Medical System President and CEO Robert ... the highest honor given to the public by the ... Dean Reece and Mr. Chrencik for their contributions ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
(Date:2/10/2016)... 10, 2016  Matchbook, Inc., a company specializing ... biotech companies, announced today the appointment of ... Jim brings nearly 25 years of experience in ... spent nearly two decades in executive level roles ... at Genzyme and, most recently headed global logistics ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/15/2016)... Rico , Jan. 15, 2016 Recent ... and small to find new ways to ensure data ... iOS and Android that ... on biometrics, transforming it into a hardware authorization token. ... users swipe their fingerprint on their KodeKey enabled device ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):